2018-2023 Global Overt Hepatic Encephalopathy Market Report (Status and Outlook)

August 2018 | 132 pages | ID: 2CD176FF34BEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Overt Hepatic Encephalopathy market for 2018-2023.

Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.
Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.
Over the next five years, LPI(LP Information) projects that Overt Hepatic Encephalopathy will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares and growth opportunities of Overt Hepatic Encephalopathy market by product type, application, key companies and key regions.

To calculate the market size, LP Information considers value generated from the sales of the following segments:

Segmentation by product type:

• Covert
• Overt

Segmentation by application:

• Hospitals
• Research Institutes
• Clinics
• Surgical Centers

We can also provide the customized separate regional or country-level reports, for the following regions:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:

• Alfa Wassermann
• Cosmo Pharmaceuticals
• Horizon Pharma
• KannaLife Sciences
• Ocer Therapeutics
• Rebiotix
• Spherium Biomed
• Umecrine Cognition
• ASKA Pharmaceutical
• Mallinckrodt
• Valeant

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Overt Hepatic Encephalopathy market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Overt Hepatic Encephalopathy market by identifying its various subsegments.
• Focuses on the key global Overt Hepatic Encephalopathy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Overt Hepatic Encephalopathy with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the size of Overt Hepatic Encephalopathy submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Overt Hepatic Encephalopathy Market Size 2013-2023
  2.1.2 Overt Hepatic Encephalopathy Market Size CAGR by Region
2.2 Overt Hepatic Encephalopathy Segment by Type
  2.2.1 Covert
  2.2.2 Overt
2.3 Overt Hepatic Encephalopathy Market Size by Type
  2.3.1 Global Overt Hepatic Encephalopathy Market Size Market Share by Type (2013-2018)
  2.3.2 Global Overt Hepatic Encephalopathy Market Size Growth Rate by Type (2013-2018)
2.4 Overt Hepatic Encephalopathy Segment by Application
  2.4.1 Hospitals
  2.4.2 Research Institutes
  2.4.3 Clinics
  2.4.4 Surgical Centers
2.5 Overt Hepatic Encephalopathy Market Size by Application
  2.5.1 Global Overt Hepatic Encephalopathy Market Size Market Share by Application (2013-2018)
  2.5.2 Global Overt Hepatic Encephalopathy Market Size Growth Rate by Application (2013-2018)

3 GLOBAL OVERT HEPATIC ENCEPHALOPATHY BY PLAYERS

3.1 Global Overt Hepatic Encephalopathy Market Size Market Share by Players
  3.1.1 Global Overt Hepatic Encephalopathy Market Size by Players (2016-2018)
  3.1.2 Global Overt Hepatic Encephalopathy Market Size Market Share by Players (2016-2018)
3.2 Global Overt Hepatic Encephalopathy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 OVERT HEPATIC ENCEPHALOPATHY BY REGIONS

4.1 Overt Hepatic Encephalopathy Market Size by Regions
4.2 Americas Overt Hepatic Encephalopathy Market Size Growth
4.3 APAC Overt Hepatic Encephalopathy Market Size Growth
4.4 Europe Overt Hepatic Encephalopathy Market Size Growth
4.5 Middle East & Africa Overt Hepatic Encephalopathy Market Size Growth

5 AMERICAS

5.1 Americas Overt Hepatic Encephalopathy Market Size by Countries
5.2 Americas Overt Hepatic Encephalopathy Market Size by Type
5.3 Americas Overt Hepatic Encephalopathy Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Overt Hepatic Encephalopathy Market Size by Countries
6.2 APAC Overt Hepatic Encephalopathy Market Size by Type
6.3 APAC Overt Hepatic Encephalopathy Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Overt Hepatic Encephalopathy by Countries
7.2 Europe Overt Hepatic Encephalopathy Market Size by Type
7.3 Europe Overt Hepatic Encephalopathy Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Overt Hepatic Encephalopathy by Countries
8.2 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Type
8.3 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET FORECAST

10.1 Global Overt Hepatic Encephalopathy Market Size Forecast (2018-2023)
10.2 Global Overt Hepatic Encephalopathy Forecast by Regions
  10.2.1 Global Overt Hepatic Encephalopathy Forecast by Regions (2018-2023)
  10.2.2 Americas Market Forecast
  10.2.3 APAC Market Forecast
  10.2.4 Europe Market Forecast
  10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
  10.3.1 United States Market Forecast
  10.3.2 Canada Market Forecast
  10.3.3 Mexico Market Forecast
  10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
  10.4.1 China Market Forecast
  10.4.2 Japan Market Forecast
  10.4.3 Korea Market Forecast
  10.4.4 Southeast Asia Market Forecast
  10.4.5 India Market Forecast
  10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
  10.5.1 Germany Market Forecast
  10.5.2 France Market Forecast
  10.5.3 UK Market Forecast
  10.5.4 Italy Market Forecast
  10.5.5 Russia Market Forecast
  10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
  10.6.1 Egypt Market Forecast
  10.6.2 South Africa Market Forecast
  10.6.3 Israel Market Forecast
  10.6.4 Turkey Market Forecast
  10.6.5 GCC Countries Market Forecast
10.7 Global Overt Hepatic Encephalopathy Forecast by Type
10.8 Global Overt Hepatic Encephalopathy Forecast by Application

11 KEY PLAYERS ANALYSIS

11.1 Alfa Wassermann
  11.1.1 Company Details
  11.1.2 Overt Hepatic Encephalopathy Product Offered
  11.1.3 Alfa Wassermann Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.1.4 Main Business Overview
  11.1.5 Alfa Wassermann News
11.2 Cosmo Pharmaceuticals
  11.2.1 Company Details
  11.2.2 Overt Hepatic Encephalopathy Product Offered
  11.2.3 Cosmo Pharmaceuticals Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.2.4 Main Business Overview
  11.2.5 Cosmo Pharmaceuticals News
11.3 Horizon Pharma
  11.3.1 Company Details
  11.3.2 Overt Hepatic Encephalopathy Product Offered
  11.3.3 Horizon Pharma Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.3.4 Main Business Overview
  11.3.5 Horizon Pharma News
11.4 KannaLife Sciences
  11.4.1 Company Details
  11.4.2 Overt Hepatic Encephalopathy Product Offered
  11.4.3 KannaLife Sciences Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.4.4 Main Business Overview
  11.4.5 KannaLife Sciences News
11.5 Ocer Therapeutics
  11.5.1 Company Details
  11.5.2 Overt Hepatic Encephalopathy Product Offered
  11.5.3 Ocer Therapeutics Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.5.4 Main Business Overview
  11.5.5 Ocer Therapeutics News
11.6 Rebiotix
  11.6.1 Company Details
  11.6.2 Overt Hepatic Encephalopathy Product Offered
  11.6.3 Rebiotix Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.6.4 Main Business Overview
  11.6.5 Rebiotix News
11.7 Spherium Biomed
  11.7.1 Company Details
  11.7.2 Overt Hepatic Encephalopathy Product Offered
  11.7.3 Spherium Biomed Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.7.4 Main Business Overview
  11.7.5 Spherium Biomed News
11.8 Umecrine Cognition
  11.8.1 Company Details
  11.8.2 Overt Hepatic Encephalopathy Product Offered
  11.8.3 Umecrine Cognition Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.8.4 Main Business Overview
  11.8.5 Umecrine Cognition News
11.9 ASKA Pharmaceutical
  11.9.1 Company Details
  11.9.2 Overt Hepatic Encephalopathy Product Offered
  11.9.3 ASKA Pharmaceutical Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.9.4 Main Business Overview
  11.9.5 ASKA Pharmaceutical News
11.10 Mallinckrodt
  11.10.1 Company Details
  11.10.2 Overt Hepatic Encephalopathy Product Offered
  11.10.3 Mallinckrodt Overt Hepatic Encephalopathy Revenue, Gross Margin and Market Share (2016-2018)
  11.10.4 Main Business Overview
  11.10.5 Mallinckrodt News
11.11 Valeant

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Table Product Specifications of Overt Hepatic Encephalopathy
Figure Overt Hepatic Encephalopathy Report Years Considered
Figure Market Research Methodology
Figure Global Overt Hepatic Encephalopa